Small-cell Lung Cancer
Conditions
Brief summary
The main purpose of this Phase 1/2 study is to determine the safety and efficacy of pegzilarginase in combination with pembrolizumab in patients with ED-SCLC who have relapsed or progressive disease on or within 6 months of platinum-based chemotherapy.
Interventions
DRUGPegzilarginase
Administered IV
DRUGPembrolizumab
Administered IV
Sponsors
Merck Sharp & Dohme LLC
Aeglea Biotherapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Patient is able and willing to provide written informed consent 2. Be \> 18 years of age on day of signing informed consent 3. Have histologically or cytologically confirmed SCLC that meets: 1. Extensive disease per criteria of the International Association for the Study of Lung Cancer (IASLC)-American Joint Committee on Cancer (AJCC) TNM staging system 2. Have not tolerated or have progressed or relapsed on or within 6 months of platinum-based chemotherapy 4. Have a performance status of ≤ 1 on the ECOG Performance Scale 5. Have measurable disease based on RECIST 1.1 6. Willing to undergo core needle or incisional biopsy to obtain fresh tumor tissue specimens 7. Demonstrate adequate organ function as evidenced by laboratory testing with specimens collected within 10 days prior to day 1 of cycle 1 8. Female child-bearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication 9. Sexually active male or female must be surgically sterile post-menopausal, or must agree to use a physician-approved method of birth control during the study through a minimum of 120 days after the last study drug administration. Key
Exclusion criteria
1. Has received more than 2 platinum-based regimens against SCLC 2. Has received pembrolizumab, or prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as part of any previous therapy, including trials 3. Has participated in Merck MK-3475 (pembrolizumab) clinical trials 4. Has received pegzilarginase as part of any previous therapy 5. Is currently participating in a study of an investigational agent or received the last dose of an investigational agent within 4 weeks prior to the first dose of treatment in this study (a shorter interval for kinase inhibitors or other short half-life drugs could be considered after approval from the Sponsor). Is currently participating in a study of an investigational device within 4 weeks of the first dose of treatment 6. Has a diagnosis of an immunodeficiency, is receiving systemic steroid therapy (except for physiological dose levels), or immunosuppressive therapies 7. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer) that has undergone potentially curative therapy 8. Has known central nervous system (CNS) metastases. However, patients with previously treated brain metastases may participate provided neurologic symptoms have stabilized, there is no evidence of new brain metastases or hemorrhage and they are not using steroids for brain metastases or for complications derived from their treatment for at least 7 days prior to the first dose of trial treatment 9. Has known carcinomatous meningitis 10. Has an active autoimmune disease requiring systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs) or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy are an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections will not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc) is not considered a form of systemic treatment 11. Has evidence of interstitial lung disease, history of non-infectious pneumonitis that required steroids, or current pneumonitis 12. Inadequately controlled hypertension (defined as systolic blood pressure ≥ 200 mmHg and/or diastolic blood pressure ≥ 120 mmHg) on more than one occasion in the month before planned day of infusion 13. Currently taking 3 or more anti-hypertensive medications 14. Prior history of hypertensive crisis or hypertensive encephalopathy 15. History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or cardiac or vascular surgery within 6 months prior to day 1 of study treatment 16. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment 17. Has a known history of Human Immunodeficiency Virus (HIV) (positive for HIV p24 antigen or HIV 1/2 antibodies) 18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected) 19. Has a known history of active tuberculosis (Bacillus tuberculosis) 20. Has had an allogenic tissue/solid organ transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1. Phase 1: Incidence of treatment-related adverse events as assessed by CTCAE v4.0 | Estimated up to 6 months | 1\. Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0. |
| Phase 2: Efficacy determined by Objective Response Rate (ORR:CR+PR) per RECIST 1.1. | Estimated up to 6 months | 1\. Objective Response Rate (ORR:) per RECIST 1.1 • The Objective Response Rate (ORR) is defined as the percentage of subjects whose best objective response (BOR) is either complete response (CR) or partial response (PR). The ORR will be derived from the BOR according to response evaluation criteria in solid tumors (RECIST) v1.1 as assessed by the Investigator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months | Percentage of patients whose cancer achieves either complete response (CR) or partial response (PR). |
| Clinical Benefit Rate | At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months | Percentage of patients who have achieved CR, PR or Stable Disease (SD), lasting at least 8 weeks. |
| Time to Response | At 9, 18, and 27 weeks after first dose and every 12 weeks thereafter up to 24 months | Time (weeks) from first treatment to the first documented CR or PR. |
| Duration of Response | At 18 and 27 weeks after first dose and every 12 weeks thereafter up to 24 months | Time (weeks) from first documented CR or PR, until disease progression (PD). |
| Progression free survival | From first treatment up to 24 months | Time (weeks) from first treatment to first observation of PD or death from any cause. |
| Overall Survival | From first treatment up to 24 months | Time (weeks) from first treatment to death due to any cause. |
| Phase 2: Incidence of treatment-related adverse events as assessed by CTCAE v4.0 | From first treatment up to 24 months | Number of participants experiencing treatment-related adverse events as assessed by CTCAE v4.0. |
Countries
Puerto Rico, United States
Outcome results
None listed